Panel: ADC Manufacturing Complexity: Technical Execution Challenges
Day 1 Next-Gen Bio Stage
06/10/2026 16:15 - 17:00pm
Contributors
Bikash Chatterjee : President and Chief Science Officer- Pharmatech Associates - A USP Company
Unmesh Lal : Vice President, Healthcare & Life Sciences - Frost & Sullivan
Amanda Cowley : Executive Vice President, Programs, Regional Operations & Strategy and Chief Growth Officer - USP
Xudong Wei : Head of Payload-Linker PD & Manufacturing - WuXi Biologics
ADC production demands highly specialised manufacturing capabilities that few facilities can provide. This panel examines the technical execution challenges in conjugation processes, containment requirements, and quality control that are creating production bottlenecks across the ADC pipeline.
- Technical complexities in achieving consistent drug-antibody ratios and managing batch-to-batch variability.
- Specialised facility requirements for handling potent cytotoxic payloads and ensuring operator safety.
- Advanced analytical methods required for ADC characterisation and release testing.